Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
Nakul KatyalKaren HalldorsdottirRaghav GovindarajanPerry B ShiehSuraj MuleyPhoebedel ReyesKenneth K LeungJeffrey MullenShadi Milani-NejadManisha KorbNamita A GoyalTahseen MozaffarNeelam GoyalThomas H BrannaganSrikanth MuppidiPublished in: Muscle & nerve (2023)
Efgartigimod led to clinically meaningful improvement in MG-ADL in diverse AChR+ve gMG patients but treatment frequency to achieve optimal symptom control needs to be explored.